17 December 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that the US Patent and Trademark Office (USPTO) has completed its examination of patent application 15/613,030, entitled: “Low oxygen culture conditions for maintaining retinal progenitor cell multipotency”, and has issued a notification of allowance for the issuance of a patent.

Read more…

11 December 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that, at the General Meeting held earlier today, all resolutions proposed were duly passed by shareholders.

Read more…

11 December 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that it has conditionally raised total gross proceeds of approximately £2.5 million through the Open Offer announced on 23 November 2020, representing the full amount proposed under the Open Offer.

Read more…

24 November 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces, further to the announcement made on 23 November 2020 by the Company (the “Launch Announcement”), the successful completion of an oversubscribed Placing, which, together with the Subscription, has conditionally raised gross proceeds for the Company of approximately £15.0 million.

Read more…

24 November 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce its interim results for the six months ended 30 September 2020.

Read more…

23 November 2020: ReNeuron Group plc (AIM: RENE.L), a UK-based global leader in the development of cell-based therapeutics, announces its intention to raise gross proceeds of up to £13.9 million by means of a placing to institutional and other investors (the “Placing“) and a direct subscription with the Company to raise gross proceeds of up to £1.1 million (the “Subscription“), in each case at a price of 70 pence per share (“Issue Price“). The net proceeds of the Placing and Subscription will allow the Group, inter alia, to deliver extended clinical data from its ongoing retinitis pigmentosa (RP) Phase 2a study and to deliver proof-of-concept pre-clinical data from ongoing exosome collaborations which could enable potential out-licensing deals, as detailed below more fully.

Read more…

10 September 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, announces that all resolutions put to shareholders at its Annual General Meeting (“AGM”) held earlier today were duly passed.

Read more…

10 September 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to provide a trading update ahead of today’s Annual General Meeting (“AGM”).

Read more…

18 August 2020: ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy development company, announces that its Annual Report and Accounts for the year ended 31 March 2020 and the Notice of the 2020 Annual General Meeting (“AGM”) have been sent to shareholders and are also available on the Company’s website at www.reneuron.com.

Read more…

A copy of the Annual Report can be found by clicking here.

31 July 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that the US Patent and Trademark office (USPTO) has completed its examination of the Company’s patent application (14/379,239), entitled: “Phenotype profile of human retinal progenitor cells” and has issued a notification of allowance for the issuance of a patent.

Read more…